Entitled “Unlocking the potential of insulin pumps for personalized T2D care,” the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D). Through a series of presentations and a panel discussion led by distinguished faculty, participants will gain insight into clinical considerations for initiating insulin pump therapy, including selection of the most suitable pump.
"We are thrilled to support this symposium as part of our ongoing commitment to fostering innovation and improving care for individuals with type 2 diabetes,” said
The symposium will be chaired by
The six embecta-sponsored abstracts set for presentation as scientific posters, include robust data about insulin therapy via both pumps and multiple daily injections (MDI). For instance, one poster by
“The research findings of
The titles and authors of the embecta-sponsored poster presentations are below:
- Insulin dosing in
U.S. adults with type 2 diabetes (T2D) on multiple daily injections (MDI): A retrospective cohort study — first author: DrViral Shah - Obesity and disparity in glycemic outcomes are prevalent among adults with type 2 diabetes on MDI: A large
U.S. retrospective cohort study — first author: Dr.Eugene Wright - Knowledge and attitudes regarding insulin pump use among adults with type 2 diabetes in
the United States — first author: Dr.Bill Polonsky - Perspectives of primary care physicians on insulin pump use for people with type 1 and type 2 diabetes in
the United States — first author: Dr.Steve Edelman - Relationship between lipohypertrophy, glycemic control, and insulin dosing: a systematic meta-analysis - EMEA region — first author: Dr.
Julia Mader - Needlestick injuries with insulin injections: risk factors, concerns, and implications of the use of safety pen needles in the
Asia-Pacific region — first author: Dr. Mafauzy Mohamed
ATTD 2024 is taking place at Fortezza da Basso,
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts: | |
Media | Investors |
Sr. Director, Corporate Communications | VP, Head of Investor Relations |
908-821-6922 | 551-264-6547 |
Contact Media Relations | Contact IR |
Source:
2024 GlobeNewswire, Inc., source